 SAN DIEGO, CA, Aug. 11, 2021 GLOBE NEWSWIRE -- Skye Bioscience, Inc. OTCQB: SKYE Skye, a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that Karam Takhar, VP of Corporate Development and Investor Relations, Skye Bioscience is scheduled to present virtually in the H.C. Wainwright Ophthalmology Conference on Tuesday, August 17 at 7:00 AM ET. 